Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03854019 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT03854019: Completed Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
NCT03854019 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03854019, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
Primary Outcome
The Irritability Scale total score ranges from 0 to 42, with higher scores indicating greater irritability.
Interventions
- DRUG Placebo
- DRUG Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2022-11-11 |
| Phase | Phase 3 |
What the finished NCT03854019 record still lists
NCT03854019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03854019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03854019 about?
NCT03854019 is a clinical study titled "Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease". The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
What is the current status of trial NCT03854019?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2019-08-05. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT03854019?
The interventions under investigation include: Placebo (DRUG), Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) (DRUG).
Who is sponsoring clinical trial NCT03854019?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03854019's enrollment target sits among peer trials
20 1956th of 2000 higher than 32 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI